Evinacumab for Homozygous Familial Hypercholesterolemia
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: ) are associated with hypolipidemia and protection against atherosclerotic cardiovascular disease. Evinacumab, a monoclonal antibody against ANGPTL3, has shown potential benefit in patients with homozygous familial hypercholesterolemia. METHODS: In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned in a 2:1 ratio 65 patients with homozygous familial hypercholesterolemia who were receiving stable lipid-lowering therapy to receive an intravenous infusion of evinacumab (at a dose of 15 mg per kilogram of body weight) every 4 weeks or placebo. The primary outcome was the percent change from baseline in the LDL cholesterol level at week 24. RESULTS: The mean baseline LDL cholesterol level in the two groups was 255.1 mg per deciliter, despite the receipt of maximum doses of background lipid-lowering therapy. At week 24, patients in the evinacumab group had a relative reduction from baseline in the LDL cholesterol level of 47.1%, as compared with an increase of 1.9% in the placebo group, for a between-group least-squares mean difference of -49.0 percentage points (95% confidence interval [CI], -65.0 to -33.1; P<0.001); the between-group least-squares mean absolute difference in the LDL cholesterol level was -132.1 mg per deciliter (95% CI, -175.3 to -88.9; P<0.001). The LDL cholesterol level was lower in the evinacumab group than in the placebo group in patients with null-null variants (-43.4% vs. +16.2%) and in those with non-null variants (-49.1% vs. -3.8%). Adverse events were similar in the two groups. CONCLUSIONS: In patients with homozygous familial hypercholesterolemia receiving maximum doses of lipid-lowering therapy, the reduction from baseline in the LDL cholesterol level in the evinacumab group, as compared with the small increase in the placebo group, resulted in a between-group difference of 49.0 percentage points at 24 weeks. (Funded by Regeneron Pharmaceuticals; ELIPSE HoFH ClinicalTrials.gov number, NCT03399786.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In total, 65 patients with HoFH were randomized to evinacumab (15 mg per kilogram body weight intravenous) or placebo every 4 weeks. Evinacumab lowered LDL-C by − 49% compared with placebo without a significant increase in adverse events. Evinacumab also significantly reduced ApoB-100 by − 37%, non-HDL by − 52%, total cholesterol by − 48%, triglycerides by − 50%, and ApoC-III by − 90%.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In comparison, evinacumab, a monoclonal antibody against ANGPTL3 that is thought to cause near-total suppression of ANGPTL3 activity, 7,14,15 reduces ApoB levels by >40% in adults with refractory hypercholesterolemia or homozygous familial hypercholesterolemia in its intravenous formulation administered at a dose of 15 mg/kg.14,15”
From Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70 (2022) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the ELIPSE HoFH trial, evinacumab significantly reduced LDL-C levels by 49% from baseline in patients with homozygous familial hypercholesterolemia (HoFH)—a population in whom standard lipid-lowering therapies (including statins and PCSK9 inhibitors) are often ineffective due to absent or defective LDL receptors [53].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [53]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These findings are confirmed in the recently published ELIPSE trial (Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia), which showed a similar LDL-C lowering effect of Evinacumab in patients with hoFH with null/null and non-null/null variants.20”
From ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia—Brief Report (2021) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Self-citationCuchel, M., Bruckert, E., Ginsberg, H. N., Raal, F. J., Santos, R. D., Hegele, R. A., Kuivenhoven, J. A., Nordestgaard, B. G., Descamps, O. S., Steinhagen-Thiessen, E., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu274 · Cited by 1,057
Self-citationMolecular genetics of the LDL receptor gene in familial hypercholesterolemia
Hobbs, H. H., Brown, M. S., & Goldstein, J. L. (1992) · Human Mutation · doi:10.1002/humu.1380010602 · Cited by 921
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
Dewey, F. E., Gusarova, V., Dunbar, R. L., O’Dushlaine, C., Schurmann, C., Gottesman, O., McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612790 · Cited by 885
Self-citationRaal, F. J., Honarpour, N., Blom, D. J., Hovingh, G. K., Xu, F., Scott, R., Wasserman, S. M., & Stein, E. A. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61374-x · Cited by 734
Self-citationKöster, A., Chao, Y. B., Mosior, M., Ford, A., Gonzalez-DeWhitt, P. A., Hale, J. E., Li, D., Qiu, Y., Fraser, C. C., Yang, D. D., et al. (2005) · Endocrinology · doi:10.1210/en.2005-0476 · Cited by 427
ANGPTL3 inhibition in homozygous familial hypercholesterolemia
Gaudet, D., Gipe, D. A., Pordy, R., Ahmad, Z., Cuchel, M., Shah, P. K., Chyu, K.-Y., Sasiela, W. J., Chan, K.-C., Brisson, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1705994 · Cited by 323
Self-citationShimamura, M., Matsuda, M., Yasumo, H., Okazaki, M., Fujimoto, K., Kono, K., Shimizugawa, T., Ando, Y., Koishi, R., Kohama, T., et al. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000252827.51626.89 · Cited by 297
Cited by
Items 201–300 of 809
Ballantyne, C. M., & Norata, G. D. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf606 · Cited by 26
May, L. T., Bartolo, B. A. D., Harrison, D. G., Guzik, T. J., Drummond, G. R., Figtree, G. A., Ritchie, R. H., Rye, K., & de Haan, J. B. (2022) · Clinical Science · doi:10.1042/cs20210862 · Cited by 24
New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3
Kim, J. Y., & Kim, N. H. (2023) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2023.12.1.23 · Cited by 23
Evinacumab: Mechanism of action, clinical, and translational science
Dingman, R., Bihorel, S., Gusarova, V., Mendell, J., & Pordy, R. (2024) · Clinical and Translational Science · doi:10.1111/cts.13836 · Cited by 23
“23 The pharmacokinetics (PK) of evinacumab has consistently shown a profile consisting of both linear and non-linear target-mediated elimination.”
BackgroundSelf-citationAlsayed, N., Almahmeed, W. A., Alnouri, F., Al-Waili, K., Sabbour, H. M., Sulaiman, K., Zubaid, M., Ray, K. K., & Al‐Rasadi, K. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.11.022 · Cited by 25
Scudeler, T. L., da Costa, L. M. A., Nunes, R. A. B., Schneidewind, R. O., Brito, T. M., Pereira, D. C. G., de Oliveira, R. P., Santana, G., Castello, H. J., Cantarelli, M. J. D. C., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-80578-w · Cited by 25
Taylan, C., Driemeyer, J., Schmitt, C. P., Pape, L., Büscher, R., Galiano, M., König, J. C., Schürfeld, C., Spitthöver, R., Versen, A., et al. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.09.015 · Cited by 22
Cardiovascular medicine: a year in review
Matteucci, A., BONANNI, M., VERSACI, F., FRATI, G., PERUZZI, M., SANGIORGI, G., Biondi‐Zoccai, G., & MASSARO, G. (2021) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.21.05816-6 · Cited by 23
Review of recent clinical trials and their impact on the treatment of hypercholesterolemia
Parham, J. S., & Goldberg, A. C. (2022) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2022.11.011 · Cited by 24
Updates in Small Interfering RNA for the Treatment of Dyslipidemias
Carugo, S., Sirtori, C. R., Gelpi, G., Corsini, A., Tokgözoğlu, L. S., & Ruscica, M. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01156-5 · Cited by 24
“Since the inhibition of ANGPTL3 by the monoclonal antibody evinacumab led to a consistent reduction of LDL-C in HoFH patients [90], ARO-ANG3 has been initially tested in HeFH patients and in non-FH patients with LDL-C > 70 mg/dL despite statins.”
BackgroundGenetic Counseling and Genetic Testing for Familial Hypercholesterolemia
Tada, H., Kawashiri, M., Nohara, A., Sekiya, T., Watanabe, A., & Takamura, M. (2024) · Genes · doi:10.3390/genes15030297 · Cited by 26
New insights into the therapeutic options to lower lipoprotein(a)
Baragetti, A., Dalt, L. D., & Norata, G. D. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14254 · Cited by 25
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
Kayki‐Mutlu, G., Aksoyalp, Z. Ş., Wojnowski, L., & Michel, M. C. (2022) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-022-02250-2 · Cited by 22
Hepatic fat changes with antisense oligonucleotide therapy targeting ANGPTL3
Zimerman, A., Wiviott, S. D., Park, J., Murphy, S. A., Ran, X., Bramson, C., Curto, M., Ramos, V., Jevne, A., Kuder, J., et al. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.12.001 · Cited by 25
Umbrella Review on Non-Statin Lipid-Lowering Therapy
Beshir, S. A., Hussain, N., Elnour, A. A., & Said, A. S. A. (2021) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484211002943 · Cited by 23
Keyes, E., Grinnell, M., Jacoby, D. S., Vazquez, T., Diaz, D., Werth, V. P., & Williams, K. J. (2021) · International Journal of Women’s Dermatology · doi:10.1016/j.ijwd.2021.08.015 · Cited by 21
New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia
Cesaro, A., Fimiani, F., Gragnano, F., Moscarella, E., Schiavo, A., Vergara, A., Akioyamen, L. E., D’Erasmo, L., Averna, M. R., Arca, M., et al. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.07.008 · Cited by 23
The Inherited Hypercholesterolemias
Loh, W. J., & Watts, G. F. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.006 · Cited by 25
Angiopoietin-like 3: An important protein in regulating lipoprotein levels
Burks, K. H., Basu, D., Goldberg, I. J., & Stitziel, N. O. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101688 · Cited by 23
Present and Future of Dyslipidaemia Treatment—A Review
Merćep, I., Vujević, A., Strikić, D., Radman, I. B., Pećin, I., & Reiner, Ž. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185839 · Cited by 25
Lipoprotein lipase as a target for obesity/diabetes related cardiovascular disease
Shang, R., & Rodrigues, B. B. (2024) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.3389/jpps.2024.13199 · Cited by 21
Albuquerque, E. L., Fulco, U. L., Caetano, E. W. S., & Freire, V. N. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108774956.011 · Cited by 21
Efficacy and Safety of Evinacumab for the Treatment of Hypercholesterolemia: A Meta-Analysis
Jin, M., Meng, F., Yang, W., Liang, L., Wang, H., & Zhenyan, F. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001073 · Cited by 22
Unravelling lipoprotein metabolism with stable isotopes: tracing the flow
Ying, Q., Chan, D. C., Barrett, P. H. R., & Watts, G. F. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154887 · Cited by 21
The year in cardiovascular medicine 2021: dyslipidaemia
Tokgözoğlu, L. S., Orringer, C. E., Ginsberg, H. N., & Catapano, A. L. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab875 · Cited by 25
Gu, Z., Liu, T., Rao, W., Li, D., Zhang, Q., Dai, J., Huang, L., Wang, J., & Hou, X. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202412335 · Cited by 20
Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA
Brinton, E. A., Eckel, R. H., Gaudet, D., Ballantyne, C. M., Baker, B. F., Ginsberg, H. N., & Witztum, J. L. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119114 · Cited by 22
Self-citationTargeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
Mohamed, F., Mansfield, B. S., & Raal, F. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12155082 · Cited by 22
“Safety and efficacy data of inclisiran, with a twice-yearly administration, could improve long-term adherence, making it a suitable alternative to traditional LLT and PCSK9 mAbs in patients who cannot achieve target LDL-C, particularly in patients with FH. 2.5.3.”
BackgroundMethodInfluentialSelf-citationClinical Characteristics of Homozygous Familial Hypercholesterolemia in Japan
Takeji, Y., Tada, H., Ogura, M., Nohara, A., Kawashiri, M., Yamashita, S., Harada‐Shiba, M., Harada‐Shiba, M., Ishibashi, S., Yokoyama, S., et al. (2023) · JACC Asia · doi:10.1016/j.jacasi.2023.07.011 · Cited by 23
Fularski, P., Hajdys, J., Majchrowicz, G., Stabrawa, M., Młynarska, E., Rysz, J., & Franczyk, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031637 · Cited by 28
“In one of the studies, as part of the clinical development of mipomersen, seven patients underwent liver biopsy after using this drug (for 23–159 weeks) [166].”
BackgroundAdvances with lipid-lowering drugs for pediatric patients with familial hypercholesterolemia
Ferrari, F., Martins, V. M., Rocha, V. Z., & Santos, R. D. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1832991 · Cited by 25
“1%) after 24 weeks in comparison with placebo in 65 homozygous FH adults [78].”
BackgroundAngiopoietin-like proteins and postprandial partitioning of fatty acids
DiDonna, N., Chen, Y. Q., & Konrad, R. J. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000798 · Cited by 20
Jo, S. (2025) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2025.14.3.247 · Cited by 20
“44”
Recent advances in research and care of familial hypercholesterolaemia
Santos, R. D., Gidding, S. S., Bourbon, M., Iatan, I., Harada‐Shiba, M., Raal, F. J., Vallejo‐Vaz, A. J., Wiegman, A., & Watts, G. F. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00286-4 · Cited by 24
Self-citationNewer and Emerging LDL-C Lowering Agents and Implications for ASCVD Residual Risk
Rikhi, R. R., & Shapiro, M. D. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154611 · Cited by 19
“The monoclonal antibody against ANGPTL3, evinacumab, has been shown to reduce LDL-C by approximately 50% in individuals with homozygous familial hypercholesterolemia on maximally tolerated lipid-lowering therapy [19].”
BackgroundResultInfluentialNew Horizons: Revival of Lipoprotein (a) as a Risk Factor for Cardiovascular Disease
Nestel, P. J., Loh, W. J., Ward, N. C., & Watts, G. F. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac541 · Cited by 21
Low cholesterol states: clinical implications and management
Gill, P. K., & Hegele, R. A. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2204932 · Cited by 19
“cholesterol with remarkable efficacy in patients with severe and refractory familial hypercholesterolemia [132,133].”
BackgroundRecent advances in the management and implementation of care for familial hypercholesterolaemia
Lan, N. S. R., Bajaj, A., Watts, G. F., & Cuchel, M. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106857 · Cited by 22
Epigenome Editing Durability Varies Widely Across Cardiovascular Disease Target Genes
Whittaker, M. N., Testa, L. C., Quigley, A., Jindal, I., Cortez-Alvarado, S. V., Qü, P., Yang, Y., Alameh, M., Musunuru, K., & Wang, X. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319748 · Cited by 21
Burks, K. H., Xie, Y., Gildea, M. A., Jung, I., Mukherjee, S. K., Lee, P. C., Pudupakkam, U., Wagoner, R., Patel, V., Santana, K., et al. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100500 · Cited by 20
“Additionally, evinacumab ’ s inhibition of circulating ANGPTL3 markedly reduced plasma lipids without reports of elevated liver function tests or hepatic fat accumulation in participants with FH (30).”
BackgroundResultChan, D. C., & Watts, G. F. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01254-y · Cited by 23
“In two phase 3 trials of patients with homozygous FH (ELIPSE HoFH) [57, 58], an IV infusion of evinacumab (15 mg/kg; Q4W) significantly reduced plasma triglycer - ide and LDL-cholesterol, non-HDL-cholesterol and HDL-cholesterol levels, with a mean reduction up to 57%, 47%, 50% and 26%, respectively.”
Bell, T. A., Liu, M., Donner, A. J., Lee, R. G., Mullick, A. E., & Crooke, R. M. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100101 · Cited by 21
“In general, clinical evaluations of ANGPTL3 therapeutics in normal and hyperlipidemic patients have replicated what have been observed in subjects with FHBL2, that inhibition of ANGPTL3 typically results in a reduction in HDL-C (13, 41, 42).”
BackgroundColesterol remanente, riesgo vascular y prevención de la arteriosclerosis
Pintó, X., Fanlo‐Maresma, M., Esteve, V., Millán, J., Blanco, A., Blasco, M., Díaz-Díaz, J. L., Rodríguez, Á. D., Mangas, A., Pascual, V., et al. (2023) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2023.02.001 · Cited by 29
New Biological Therapies for Low-Density Lipoprotein Cholesterol
Gill, P. K., & Hegele, R. A. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.08.003 · Cited by 20
Angiopoietin-like 3 inhibition and the liver: less is more?
Oostveen, R. F., Hovingh, G. K., & Stroes, E. S. G. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000898 · Cited by 18
“In these patients, the vast majority had an increased body (15 mg/kg i.v. administration was reported, without any notable changes in liver transaminases [20 && ].”
BackgroundSelf-citationRole of the angiopoietin-like protein family in the progression of NAFLD
Su, X., Xu, Q., Li, Z., Ren, Y., Jiao, Q., Wang, L., & Wang, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27739 · Cited by 21
Tarugi, P., Bertolini, S., Calandra, S., Arca, M., Angelico, F., Casula, M., Cefalu, A. B., D’Erasmo, L., Fortunato, G., Filardi, P. P., et al. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.05.002 · Cited by 20
Self-citationPast, Present, and Future of Familial Hypercholesterolemia Management
Rocha, V. Z., & Santos, R. D. (2021) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.887 · Cited by 26
Transcriptomic Therapy for Dyslipidemias Utilizing Nucleic Acids Targeted at ANGPTL3
Watts, G. F., Raal, F. J., & Chan, D. C. (2021) · Future Cardiology · doi:10.2217/fca-2021-0096 · Cited by 18
Self-citationRecent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention
Quispe, R., Sweeney, T. E., Varma, B., Agarwala, A., & Michos, E. D. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01052-4 · Cited by 18
Tandirerung, F. J. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01783-5 · Cited by 20
Bell, A. S., Rosoff, D. B., Mavromatis, L. A., Jung, J., Wagner, J., & Lohoff, F. W. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.026122 · Cited by 17
Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions
Tramontano, D., Bini, S., Maiorca, C., Di Costanzo, A., Carosi, M., Castellese, J., Arizaj, I., Commodari, D., Covino, S., Sansone, G., et al. (2025) · Drugs · doi:10.1007/s40265-025-02158-0 · Cited by 17
Saadatagah, S., Larouche, M., Naderian, M., Nambi, V., Brisson, D., Kullo, I. J., Duell, P. B., Michos, E. D., Shapiro, M. D., Watts, G. F., et al. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.03.012 · Cited by 30
“83,84 86 The efficacy of these agents has been assessed in patients with mixed dyslipidemia, mHTG, sHTG, and eHTG, demonstrating up to 82% TG reductions, but none are currently in ongoing development for the treatment of chylomicronemia.”
Self-citationMormone, A., Tortorella, G., Esposito, F., Caturano, A., Marrone, A., Cozzolino, D., Galiero, R., Marfella, R., Sasso, F. C., & Rinaldi, L. (2024) · Biomedicines · doi:10.3390/biomedicines12020432 · Cited by 19
ANGPTL3 Downregulation Increases Intracellular Lipids by Reducing Energy Utilization
Pennisi, G., Maurotti, S., Ciociola, E., Jamialahmadi, O., Bertolazzi, G., Mirarchi, A., Bergh, P., Scionti, F., Mancina, R. M., Spagnuolo, R., et al. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319789 · Cited by 18
D’Erasmo, L., Bini, S., Casula, M., Gazzotti, M., Bertolini, S., Calandra, S., Tarugi, P., Averna, M. R., Iannuzzo, G., Fortunato, G., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae036 · Cited by 19
Management of dyslipidemia in coronary artery disease: the present and the future
Dimitriadis, K. S., Theofilis, P., Iliakis, P., Pyrpyris, N., Dri, E., Sakalidis, A., Σουλαϊδόπουλος, Σ., Tsioufis, P., Fragkoulis, C., Chrysohoou, C. A., et al. (2024) · Coronary Artery Disease · doi:10.1097/mca.0000000000001375 · Cited by 23
“In 65 patients with homozygous familial hypercholesterolemia, a mean LDL-C change of 49% was observed with evinacumab compared to placebo [85].”
Modder, M., Panhuis, W. I. H., Li, M., Afkir, S., Dorn, A. L., Pronk, A. C. M., Streefland, T. C. M., Lalai, R. A., Pierrou, S. E., Nilsson, S. K., et al. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae195 · Cited by 20
Luo, S., Zheng, M., Wong, V. W., & Yeung, S. L. A. (2024) · eGastroenterology · doi:10.1136/egastro-2024-100114 · Cited by 19
“…are under investigation, including pharmaceutical inhibition, hepatically-targeted antisense oligonucleotide inhibition (Vupanorsen), 52 neutralisation of circulating ANGPTL3 protein by monoclonal antibodies (Evinacumab) 53 and CRISPR gene editing to introduce LoF mutations in ANGPTL3 locus.”
An overview of persistent chylomicronemia: much more than meets the eye
Larouche, M., Watts, G. F., Ballantyne, C. M., & Gaudet, D. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000903 · Cited by 17
Self-citationStatin intolerance: new data and further options for treatment
Diaconu, C. C., Iorga, R., Furtunescu, F., Katsiki, N., Stoian, A. P., & Rizzo, M. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000874 · Cited by 17
Page, M. M., Hardikar, W., Alex, G., Bates, S., Srinivasan, S., Stormon, M., Hall, K., Evans, H., Johnston, P. S., Chen, J. L., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117305 · Cited by 18
Reeskamp, L. F., Tromp, T. R., Huijgen, R., Stroes, E. S. G., Hovingh, G. K., & Grefhorst, A. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.11.013 · Cited by 21
Self-citationHu, X., Nan, Y., Zhang, Y., Fan, J., Wang, H., Bai, Y., Zhang, Y., Zhang, X., Zhu, Z., Cao, Z., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107486 · Cited by 18
Self-citationSaadatagah, S., Larouche, M., Naderian, M., Nambi, V., Brisson, D., Kullo, I. J., Duell, P. B., Michos, E. D., Shapiro, M. D., Watts, G. F., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.100978 · Cited by 22
“Evinacumab (a monoclonal antibody), zodasiran (siRNA), and sol-binsiran (siRNA) are ANGPTL3 inhibitors that can treat a large spectrum of lipid disorders, from severe refractory hypercholesterolemia to chy-lomicronemia [83,84].”
Self-citationReijman, M. D., Defesche, J. C., & Wiegman, A. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000863 · Cited by 17
ANGPTL4: a new mode in the regulation of intravascular lipolysis
Ploug, M. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000800 · Cited by 16
Vekić, J., Zeljković, A., Stefanović, A., Bogavac‐Stanojević, N., Ilias, Ι., Silva‐Nunes, J., Stoian, A. P., Janež, A., & Rizzo, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040825 · Cited by 17
“TG levels by 49% and 50%, respectively [57].”
BackgroundWadström, B. N., Pedersen, K. M., Wulff, A. B., & Nordestgaard, B. G. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000867 · Cited by 17
Evinacumab for treatment of familial hypercholesterolemia
Warden, B. A., & Duell, P. B. (2021) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2021.1955349 · Cited by 16
“Phase III study in patients with HoFH [57] 65 15 mg/kg IV every 4 weeks (N = 43) Placebo IV every 4 weeks (N = 22) LDL-C: 255 mg/dL ApoB: 171 mg/dL HDL-C: 44 mg/dL Non-HDL-C: 278 mg/dL TC: 322 mg/dL TG: 97 mg/dL Lp(a): 57 nmol/L Statin: 94% High intensity statin: 77% Ezetimibe: 75% PCSK9i: 77% Lomitapide: 25% Apheresi…”
BackgroundInfluentialRare coding variants in CHRNB2 reduce the likelihood of smoking
Rajagopal, V. M., Watanabe, K., Mbatchou, J. S., Ayer, A. H., Quon, P., Sharma, D., Kessler, M. D., Praveen, K., Gelfman, S., Parikshak, N., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01417-8 · Cited by 15
Stefanutti, C., Chan, D. C., Zeppa, G., & Watts, G. F. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.05.006 · Cited by 17
Shaik, A., & Rosenson, R. S. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07168-0 · Cited by 16
“4% decrease in apoB levels from baseline, as well as a significant reduction in TG levels [132].”
BackgroundSelf-citationTargeting angiopoietin‐like 3 in atherosclerosis: From bench to bedside
Ling, P., Zheng, X., Luo, S., Ge, J., Xu, S., & Weng, J. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14450 · Cited by 16
“Influenzalike illness (11%), headache (11%) and urinary tract infection (11%) were the most frequent adverse events among patients treated with evinacumab, followed by injection-site erythaema (6%), arthralgia (5%), myalgia (5%), and elevations of the alanine aminotransferase level (3%).(3,62) Only one study reported…”
BackgroundResultInfluentialHow ANGPTL3 Inhibition Will Help Our Clinical Practice?
Bini, S., Tramontano, D., Minicocci, I., Costanzo, A. D., Tambaro, F., D’Erasmo, L., & Arca, M. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01076-w · Cited by 15
Khoury, É., Lauzière, A., Raal, F. J., Mancini, J., & Gaudet, D. (2022) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytad029 · Cited by 15
“A fully monoclonal antibody against ANGPTL3, evinacumab, underwent advanced clinical development and was shown to be safe and effective in combination with standard-of-care LLTs in HoFH under a Phase 2 proof-of-concept trial(10) and the Phase 3 ELIPSE study.(11) Evinacumab was approved by the Food and Drug Administrat…”
MethodSelf-citationFamilial Hypercholesterolemia: Challenges for a High-Risk Population
Choi, D., Malick, W. A., Köenig, W., Rader, D. J., & Rosenson, R. S. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.02.038 · Cited by 16
Self-citationHepatokines, bile acids and ketone bodies are novel Hormones regulating energy homeostasis
Garruti, G., Baj, J., Cignarelli, A., Perrini, S., & Giorgino, F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1154561 · Cited by 16
“By contrast, knockout mice for ANGPTL6 show an increased incidence of obesity, insulin resistance, and increased fat content in peripheral organs (especially the liver and skeletal muscle) (42).”
BackgroundHow to Handle Elevated Triglycerides: Life after PROMINENT
Pirillo, A., & Catapano, A. L. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01175-2 · Cited by 16
“It was shown to halve LDL-C levels [23], leading to its approval for this category of patients.”
Familial hypercholesterolemia – treatment update in children, systematic review
Ziółkowska, S., Kijek, N., Zendran, I., Szuster, E., & Barg, E. (2022) · Pediatric Endocrinology Diabetes and Metabolism · doi:10.5114/pedm.2022.116112 · Cited by 15
“1% in the ELIPSE-HoHF Study at 24 weeks of evinacumab treatment [83].”
BackgroundEvaluation of Plasma Biomarkers for Causal Association With Peripheral Artery Disease
Sharma, P., Levin, M. G., Klarin, D. M., Voight, B. F., Tsao, P. S., & Damrauer, S. M. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.320674 · Cited by 15
Sheth, S., Banach, M., & Toth, P. P. (2024) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2024.2398444 · Cited by 16
“In patients with homozygous familial hypercholesterolemia, intravenous infusion of the anti-ANGPTL3 monoclonal antibody evinacumab reduces LDL-C from a baseline of 255.1 mg/dL by 47.1% at 24 weeks of infusion every 4 weeks, compared to a 1.9% increase in LDL-C for the placebo group [34].”
InfluentialVahdat‐Lasemi, F., Farhoudi, L., Hosseinikhah, S. M., Santos, R. D., & Sahebkar, A. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119235 · Cited by 14
Jianu, N., Nițu, E.-T., Merlan, C., Nour, A., Buda, S., Suciu, M., Luca, S. A., Sbârcea, L., Andor, M., & Buda, V. O. (2025) · Pharmaceuticals · doi:10.3390/ph18081150 · Cited by 20
Zhou, R., Stouffer, G. A., & Smith, S. C. (2021) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484211023632 · Cited by 15
“Lomitapide is now licensed in the United Kingdom and the United States but is restricted to use in homozygous familial hypercholesterolemia (FH).40 Another lipid regulator mipomersen, an apolipoprotein B antisense oligonucleotide, has been used for treatment of homozygous FH. Mipomersen induces degradation of the apoB…”
BackgroundInfluentialStatin intolerance and new lipid-lowering treatments
Mesi, O., Lin, C., Ahmed, H. M., & Cho, L. S. (2021) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.88a.20165 · Cited by 17
Powell, D. R., Revelli, J., Doree, D. D., DaCosta, C. M., Desai, U., Shadoan, M. K., Rodriguez, L., Mullens, M., Yang, Q. M., Ding, Z., et al. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s322083 · Cited by 16
Evinacumab: a new option in the treatment of homozygous familial hypercholesterolemia
Pirillo, A., & Catapano, A. L. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2090242 · Cited by 15
Inhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia
Larouche, M., Khoury, É., Brisson, D., & Gaudet, D. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01179-y · Cited by 15
“The favorable results of the phase 2 and phase 3 studies [42–44] allowed the registration of this agent for HoFH in several countries.”
Self-citationRen, Z., Zhou, J., Yang, D., Guo, Y., Zhang, J., Xu, J., & Chen, Y. E. (2026) · Cells · doi:10.3390/cells15020134 · Cited by 15
“CRISPR/Cas9 delivery via LNP also enabled efficient, liver-specific silencing of ANGPTL3 in mice, significantly reducing LDL-C and triglyceride levels without off-target effects or liver toxicity [128].”
Secondary Prevention after Myocardial Infarction: What to Do and Where to Do It
Tuka, V., Holub, J., & Bělohlávek, J. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2306210 · Cited by 20
“, inclisiran [55], anacetrapib [56,57], evinacumab (ANGPTL3 inhibitor) [58], bempedoic acid [59], pelacarsen [60] but none of them have available data in patients after ACS yet.”
BackgroundJacobsen, A. P., Whelton, S. P., Blumenthal, R. S., & McEvoy, J. W. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88369-6.00042-6 · Cited by 22
Bhat, O. M., Mir, R. A., Nehvi, I. B., Wani, N. A., Dar, A. H., & Zargar, M. A. (2024) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2024.101469 · Cited by 18
Recent progress in gene therapy for familial hypercholesterolemia treatment
Luo, Y., Hou, Y., Zhao, W., & Yang, B. (2024) · iScience · doi:10.1016/j.isci.2024.110641 · Cited by 15
“149 However, it is important to note that the safety and efficacy of ANGPTL3-targeted therapies still require long-term follow-up to determine their impact on ASCVD risks and any potential adverse effects or complications.”
BackgroundMaidman, S. D., Hegele, R. A., & Rosenson, R. S. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01258-8 · Cited by 14
“They reported a primary endpoint of 49% point between group difference in LDL cholesterol level reduction [59].”
InfluentialSelf-citationAdvances in Oral Biomacromolecule Therapies for Metabolic Diseases
Jiao, Q., Huang, Y., He, J., & Xu, Y. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17020238 · Cited by 13
Novel Therapeutics for Familial Chylomicronemia Syndrome
Izar, M. C. D. O., & Fonseca, F. A. H. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01295-x · Cited by 14
“Evinacumab has been administered intravenously at a dose of 15 mg/kg every four weeks in clinical studies [52, 53].”
Novel therapies for familial hypercholesterolemia
Mohamed, F., Seedat, F., & Raal, F. J. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000590 · Cited by 16
Self-citationAverna, M. R., & Catapano, A. L. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.10.017 · Cited by 14
Metadata
- Authors
- Raal, F. J., Rosenson, R. S., Reeskamp, L. F., Hovingh, G. K., Kastelein, J. J. P., Rubba, P., Ali, S., Banerjee, P., Chan, K.-C., Gipe, D. A., Khilla, N., Pordy, R., Weinreich, D. M., Yancopoulos, G. D., Zhang, Y., & Gaudet, D.
- Affiliations
- University of the Witwatersrand (ZA)
- Regeneron (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-08-20
- Volume
- 383
- Issue
- 8
- Pages
- 711-720
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3061843793
- Semantic Scholar
- 9f8bdc77b195a0ec05f5cb5d0662d5a8c5e0b865
- Cited by
- 793
- References
- 24
- Citations by year
- 2026: 126 · 2025: 129 · 2024: 139 · 2023: 123 · 2022: 130 · 2021: 123 · 2020: 22
- FWCI
- 91.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- evinacumab, homozygous familial hypercholesterolemia, ANGPTL3, LDL cholesterol lowering, monoclonal antibodies, lipid-lowering therapy, atherosclerotic cardiovascular disease prevention
- MeSH terms
- Angiopoietin-like Proteins, Angiopoietin-Like Protein 3, Adolescent, Adult, Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Child, Double-Blind Method, Female, Homozygote, Humans, Hyperlipoproteinemia Type II, Infusions, Intravenous, Cholesterol, LDL, Male, Middle Aged, Mutation, Receptors, LDL, Least-Squares Analysis, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.